JP Morgan Healthcare Conference
Pacific Biosciences CEO Discusses Q4 Results, New Sequencing Platforms at JP Morgan
The sequencing company reported preliminary fourth quarter revenues of $27 million and said it currently has $318 million in cash and investments.
JP Morgan Healthcare Conference 2021, Day 3: Exact Sciences, Danaher, NanoString, Bio-Techne, More
Exact Sciences discussed new Cologuard data; Danaher reviewed Cepheid's 2020 performance; and NanoString talked about forthcoming spatial biology products.
At JP Morgan Conference, Quidel CEO Discusses Plan to Enter OTC Infectious Disease Test Market
The firm plans to begin its OTC efforts with a COVID antigen test but also sees potential in migrating other infectious disease tests.
JP Morgan Healthcare Conference 2021, Day 1: Qiagen, Invitae, Agilent, Sema4, More
Qiagen's CEO discussed the company's focus on specific growth drivers, while Invitae's CEO talked about pandemic-related challenges in its genetic testing business.
At JPM, Natera CEO Lays Out Growth Potential for NIPT, Transplant, Cancer Testing
Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing.Â